Advertisement

Topics

Ibrutinib Approval Expanded to Include Chronic GVHD

01:06 EDT 4 Aug 2017 | Cancer Networks

The US Food and Drug Administration has approved the tyrosine kinase inhibitor ibrutinib (Imbruvica) for adult patients with chronic graft vs host disease who have failed on one or more lines of prior systemic therapy.

Original Article: Ibrutinib Approval Expanded to Include Chronic GVHD

NEXT ARTICLE

More From BioPortfolio on "Ibrutinib Approval Expanded to Include Chronic GVHD"

Quick Search
Advertisement